Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in Advanced Gastric Cancer

Inclusion Criteria: 1. Patients shall have normal organic function such as liver function, Cardiac function and renal function; 2. age \>18 years old; 3. diagnosis metastatic colorectal cancer with histology; 4. Did not received first-line chemotherapy 5. Karnofsky Performance scores should be 60,70,or80 6. should have target lesions or non-target lesions 7. For patients received oxaliplatin before, the residual neurotoxicity should less than grade 2 8. For diabetes without neuropathy, blood glucose before meal should less than 8mmol/L and HBA1C\<7.0% 9. Patients should be expected to live no shorter than 3 months Exclusion Criteria: 1. patients who is receiving chemotherapy; 2. WBC\<4.0×109/L，ANC\<1.5×109/L,PLT\<100×109/L，Hb\<90g/L,TBIL\>1.5Limitation;BUN）\>1.5Limitation；Cr）\>1.5Limitation；ALT or AST\>2.5Limitation（without liver metastasis）；ALT or AST）\>5Limitation（with liver metastasis）; 3. heart dysfunction; 4. brain metastasis; 5. peripheral nervous system or central nervous system abnormal including diabetes mellitus patients with neuropathy; 6. patients who received Glutathione, acetylcysteine, calcium / magnesium, amifostine, carbamazepine, B vitamins, vitamin E within 30 days